Multi Drug Resistant Tuberculosis
DOI:
https://doi.org/10.15584/ejcem.2019.3.11Keywords:
BACTEC, MDRTB, multi drug resistant tuberculosis, Mycobacterium, tuberculosisAbstract
Introduction. Tuberculosis is one of the oldest infections known to mankind. Of all infectious diseases, tuberculosis causes the most fatalities of any infection. The incidence of tuberculosis on the rise due to the increased prevalence of HIV infection. The incidence of drug resistance strains of mycobacterium is also on the rise. When the mycobacterium is resistant to both INH and rifampicin it is called multi drug resistant tuberculosis. There is a primary and an acquired type of drug resistance. Multidrug resistant tuberculosis is a not only a problem for the patient but also for society at large. The treatment of multidrug resistant tuberculosis requires an entirely different approach.
Aim. In this review, we are going to describe the etiopathogenesis, diagnosis, investigations and treatment of multi drug resistant tuberculosis.
Material and methods. Analysis of the current literature.
Results. Genetic factors, previous treatment, and other factors predisposes the onset of drug resistance. By early detection and prevention of spread of drug resistant strains we can prevent the spread of resistant strains.
Conclusion. Drug resistance in tuberculosis is a very complex and dangerous problem. We have to prevent the development and spread of MDRTB. Good quality drugs should be used and made available to all sections of the population. Enhancing the National tuberculosis programs is the best way to attain an effective way to control this menace.
Downloads
References
Barberis I, Bragazzi NL, Galluzzo L, Martini M. The history of tuberculosis: from the first historical records to the isolation of Koch’s bacillus. J Prev Med Hyg. 2017;58(1):E9-E12.
Wells C, Cegielski J, Nelson L, et al. HIV Infection and Multidrug‐Resistant Tuberculosis—The Perfect Storm. J Infect Dis. 2000;196(s1):86-107.
Glaziou P, Sismanidis C, Floyd K, Raviglione M. Global Epidemiology of Tuberculosis. Cold Spring Harb Perspect Med. 2015;5(2):a017798-a017798.
Smith I. Mycobacterium tuberculosis Pathogenesis and Molecular Determinants of Virulence. Clin Microbiol Rev. 2003;16(3):463-496.
Brites D, Gagneux S. Co-evolution of Mycobacterium tuberculosis and Homo sapiens. Immunol Rev. 2015;264(1):6-24.
Honigsbaum M. René Dubos, tuberculosis, and the “ecological facets of virulence”. Hist Philos Life Sci. 2017 Sep;39(3):15.
Long R. Making a Timely Diagnosis of Pulmonary Tuberculosis. Canadian Respiratory Journal. 2015;22(6):317-321.
Gopalan N, Chandrasekaran P, Swaminathan S, Tripathy S. Current trends and intricacies in the management of HIV-associated pulmonary tuberculosis. AIDS Res Ther. 2016;13(1).
Heemskerk D, Caws M, Marais B, et al. Tuberculosis in Adults and Children. London; Springer: 2015.
Burhan E, Ruesen C, Ruslami R, et al. Isoniazid, Rifampin, and Pyrazinamide Plasma Concentrations in Relation to Treatment Response in Indonesian Pulmonary Tuberculosis Patients. Antimicrob. Agents Chemother. 2013;57(8):3614-3619.
Leibert E, Rom WN. New drugs and regimens for treatment of TB. Expert Rev Anti Infect Ther. 2010;8(7):801-813.
Caminero JA, Sotgiu G, Zumla A, Migliori GB. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. The Lancet Infectious Diseases. 2010;110(9):621-629.
Chhabra N, Aseri ML, Dixit R, Gaur S. Pharmacotherapy for multidrug resistant tuberculosis. JPP. 2012;3(2):98-104.
Rendon A, Tiberi S, Scardigli A, et al. Classification of drugs to treat multidrug-resistant tuberculosis (MDR-TB): evidence and perspectives. J Thorac Dis. 2016;8(10):2666-2671.
Chahine EB, Karaoui LR, Mansour H. Bedaquiline. Ann Pharmacother. 2014;48(1):107-115.
Ehlers S, Schaible UE. The Granuloma in Tuberculosis: Dynamics of a Host–Pathogen Collusion. Front Immunol. 2013;3:411.
Dutta NK, Karakousis PC. Latent Tuberculosis Infection: Myths, Models, and Molecular Mechanisms. Microbiol Mol Biol Rev. 2014;78(3):343-371.
World Health Organization. Global Tuberculosis Report (2017). www.who.int. Assessed 27 July 2019.
Gunther G. Multidrug-resistant and extensively drug-resistant tuberculosis: a review of current concepts and future challenges. Clin Med .2014;14(3):279-285.
Hamusse SD, Teshome D, Hussen MS, Demissie M, Lindtjørn B. Primary and secondary anti-tuberculosis drug resistance in Hitossa District of Arsi Zone, Oromia Regional State, Central Ethiopia. BMC Public Health. 2016;16(1).
Ershova JV, Volchenkov GV, Kaminski DA, et al. Epidemiology of Primary Multidrug-Resistant Tuberculosis, Vladimir Region, Russia. Emerg Infect Dis. 2015;21(11):2048-2051.
Palomino J, Martin A. Drug Resistance Mechanisms in Mycobacterium tuberculosis. Antibiotics. 2014;3(3):317-340.
Migliori GB, Matteelli A, Cirillo D, Pai M. Diagnosis of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis: Current standards and challenges. Can J Infect Dis Med Microbiol. 2008;19(2):169-172.
Dash M. Drug resistant tuberculosis: A diagnostic challenge. J Postgrad Med. 2013;59(3):196.
Balabanova Y, Drobniewski F, Nikolayevskyy V, et al. An Integrated Approach to Rapid Diagnosis of Tuberculosis and Multidrug Resistance Using Liquid Culture and Molecular Methods in Russia. PLoS ONE. 2009;4(9):e7129.
Niemann S, Harmsen D, Rüsch-Gerdes S, Richter E. Differentiation of Clinical Mycobacterium tuberculosis Complex Isolates by gyrB DNA Sequence Polymorphism Analysis. J Clin Microbiol. 2000;38(9):3231-3234.
Banaiee N, Bobadilla-del-Valle M, Bardarov S, et al. Luciferase Reporter Mycobacteriophages for Detection, Identification, and Antibiotic Susceptibility Testing of Mycobacterium tuberculosis in Mexico. J Clin Microbiol. 2001;39(11):3883-3888.
Imperiale BR, Cataldi AA, Morcillo NS. Rapid detection of multidrug-resistant Mycobacterium tuberculosis by multiplex allele-specific polymerase chain reaction. Int J Tuberc Lung Dis. 2011;15(4):496-501.
Mulu W, Mekkonnen D, Yimer M, Admassu A, Abera B. Risk factors for multidrug resistant tuberculosis patients in Amhara National Regional State. Afr H Sci. 2015;15(2):368.
Gaude G, Hattiholli J, Kumar P. Risk factors and drug-resistance patterns among pulmonary tuberculosis patients in northern Karnataka region, India. Niger Med J. 2014;55(4):327.
Lomtadze N, Aspindzelashvili R, Janjgava M, et al. Prevalence and Risk Factors for Multidrug-Resistant Tuberculosis in Republic of Georgia: A Population Based Study. Int J Tuberc Lung Dis. 2009;13(1):68-73.
Menon S. Preventing Nosocomial MDR TB Transmission in sub Saharan Africa: Where Are We at?. Glob J Health Sci. 2013;5(4):200-210.
Fox G, Schaaf H, Mandalakas A, Chiappini E, Zumla A, Marais B. Preventing the spread of multidrug-resistant tuberculosis and protecting contacts of infectious cases. Clin Microbiol Infect. 2017;23(3):147-153.
Companion Handbook to the WHO Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis. Geneva: World Health Organization; Treatment strategies for MDR-TB and XDR-TB.2014.
Udwadia Z, Moharil G. Multidrug-resistant-tuberculosis treatment in the Indian private sector: Results from a tertiary referral private hospital in Mumbai. Lung India. 2014;31(4):336.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2019 European Journal of Clinical and Experimental Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.
All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.
